Previous 10 | Next 10 |
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases and conditions, today announces ...
QSAM Biosciences (OTCQB: QSAM) , a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions, today announced the addition of the Ellis Fischel Cancer Center at the Universi...
Austin, TX, Feb. 22, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases and conditions, today announces ...
Cancer treatments often take a huge toll on the patient’s body, causing adverse side effects such as blood clots, nausea and vomiting, hair loss, lymphedema and neutropenia. Neutropenia refers to the loss of neutrophils , which are a type of white blood cell. In severe neutropenia cases...
Cancer is the second leading cause of death in the United States after heart disease, accounting for an estimated 602,350 deaths in 2020 and 608,570 deaths in 2021 . Although we still don’t know exactly what causes normal cells to become cancerous, scientists have narrowed down several...
Researchers at St. Jude’s Children Research Hospital have conducted a new study looking into drug sensitivity among patients with acute lymphoblastic leukemia across a variety of genetic subtypes. Acute lymphoblastic leukemia is a common childhood cancer that affects white blood cells....
QSAM Biosciences (OTCQB: QSAM) , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSA...
AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases, today provides the follo...
Lung cancer is the deadliest type of cancer in the United States, causing more than 100,000 deaths annually, which is more casualties than other kinds of cancers combined . Current lung-cancer treatments include chemotherapy, surgery, targeted therapy, radiation therapy or a combination of these...
Researchers have discovered that crossword puzzles help to better sharpen memory in older individuals suffering from mild cognitive impairment, in comparison to computer games. While crossword puzzles are popularly used, no research has systematically studied them and their association with mil...
News, Short Squeeze, Breakout and More Instantly...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...
QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...